{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-219367","form_type":"8-K","ticker":"IMNM","cik":"0001472012","company_name":"Immunome Inc.","filed_at":"2026-05-12T20:05:17+00:00","discovered_at":"2026-05-12T20:07:00.310971+00:00","generated_at":"2026-05-12T21:36:02.746546+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Immunome Q1 2026 net loss $53.8M; NDA filed for varegacestat; cash $582.7M","bullets":["Net loss of $53.8M; R&D expenses $46.4M (incl. $3.7M stock comp); G&A $13.0M (incl. $4.2M stock comp).","Cash and equivalents $582.7M at March 31, 2026; expected to fund operations into 2028.","NDA submitted to FDA in April 2026 for varegacestat for desmoid tumors; Phase 3 RINGSIDE data selected for oral presentation at ASCO 2026.","Phase 1 trial of IM-1021 ongoing with objective responses in B-cell lymphoma; initial lymphoma data expected in 2026.","IND clearance for IM-1617 (first-in-class ADC) in April 2026; INDs for IM-1340 and IM-1335 planned mid/late 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-219367","json":"https://secwatch.observer/filing/0001193125-26-219367.json","markdown":"https://secwatch.observer/filing/0001193125-26-219367.md","text":"https://secwatch.observer/filing/0001193125-26-219367.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472012/000119312526219367/0001193125-26-219367-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472012/000119312526219367/imnm-20260512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T21:36:02.746546+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b7f54ec1ae3a0115b80af6edd40dddb754bd96df","claim":"Immunome Inc. reported the quarter ended March 31, 2026 results: net income net loss of $53.8 million.","evidence_excerpt":"Immunome reported a net loss of $53.8 million for the quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1472012/000119312526219367/0001193125-26-219367-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2026"},{"label":"Net income","value":"net loss of $53.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}